Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Osteosarcoma
is the most common primary malignant bone tumor that mostly affects young people's health. The prognosis of patients with unresectable or
recurrent osteosarcoma
still remains dismal. Based on gene integration analysis from GEO and TARGET databases by R language, the differentially expressed genes of
osteosarcoma
patients were identified. Biological molecular function analysis indicated that these genes were importantly enriched in the process of cell adhesion molecule binding. Gene significance highly-related to clinical traits of
osteosarcoma
was found by weighted gene co-expression network analysis. Additionally, receiver operating characteristic curve analysis was conducted to find prognostic markers in LASSO Cox regression model. Two candidate biomarkers,
ANXA1
and
PSAT1
, for the prognosis of
osteosarcoma
were detected separately on the basis of WGCNA and LASSO model. Of note, their expression profiles were interrelated with an important therapeutic target
HSPA5
.
In vitro
pharmaceutical experiments were performed to explore the biological role and prognostic benefit of candidates. Suppression of
HSPA5
effectively upregulated
ANXA1
and inhibited
PSAT1
, resulting in
osteosarcoma
cell proliferation arrest and apoptosis. These findings suggest that
HSPA5
serves as a core molecule for
osteosarcoma
therapy due to its bidirectional regulation of candidate prognostic biomarkers
ANXA1
and
PSAT1
.
...
PMID:Therapeutic potential of targeting
HSPA5
through dual regulation of two candidate prognostic biomarkers
ANXA1
and
PSAT1
in osteosarcoma. 3329 Oct 71
<< Previous
1
2
3
4